1-3 of 3
Thomas A. Ollila
Close
Sort by
Journal Articles

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy

Clinical Trials & Observations
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason Romancik, Tamara K. Moyo, Vaishalee Kenkre, Thomas A. Ollila, Lindsey Fitzgerald, Brian Hess, Kevin David, Ishan Roy, Joanna Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S. Bhansali, Elyse I. Harris, Jieqi Liu, Imran Nizamuddin, Shuo Ma, Jonathan Moreira, Jane Winter, Barbara Pro, Deborah M. Stephens, Alexey Danilov, Nirav N. Shah, Jonathon B. Cohen, Stefan K. Barta, Pallawi Torka, Leo I. Gordon
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2592–2599.
https://doi.org/10.1182/bloodadvances.2023011996
Published: 2024
Journal Articles

Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis

Thomas A. Ollila, Rashida Taher, Prashanth Moku, Adam J. Olszewski
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5470–5479.
https://doi.org/10.1182/bloodadvances.2023010352
Published: 2023
Journal Articles

Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma

Clinical Trials & Observations
Adam J. Olszewski, Anna D. Chorzalska, Max Petersen, Thomas A. Ollila, Adam Zayac, Habibe Kurt, Diana O. Treaba, John L. Reagan, Andrew Hsu, Pamela C. Egan, James Butera, Rabin Niroula, John Vatkevich, Jordan Robison, Ilyas Sahin, Allison P. Jacob, Chelsea D. Mullins, Patrycja M. Dubielecka
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5525–5535.
https://doi.org/10.1182/bloodadvances.2021004512
Published: 2021
Includes: Supplemental data